If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...
In 2025, DriveItAway continued its transition from early-stage innovation to national execution, anchored by strengthened governance, expanded market presence, and growing validation of its flexible ...
House Digest on MSN
13 ideas to landscape a no-mow yard
A no-mow yard saves you time and money. There are many ways to approach it, depending on your region and aesthetic, from ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...
SEATTLE--(BUSINESS WIRE)--Dec 24, 2025-- ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Complement activation may promote atherosclerosis. Yet, data on the to which extent complement, and more specifically the alternative complement pathway, is activated in patients with carotid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback